• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Rare Abiotrophia Endocarditis Shows High Surgery Rates in Systematic Case Review

by
November 14, 2026
in Health
Reading Time: 3 mins read
0
Rare Abiotrophia Endocarditis Shows High Surgery Rates in Systematic Case Review

Rare Abiotrophia Endocarditis Shows High Surgery Rates in Systematic Case Review

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A systematic review examining published global case reports of infective endocarditis caused by Abiotrophia defectiva has found that the rare and fastidious bacterial infection predominantly affects younger males, frequently involves the mitral valve, and leads to surgical intervention in more than seventy percent of documented cases. Although short-term clinical recovery was documented in almost all published reports, the investigators stressed that the available evidence carries very low certainty due to inherent reporting, publication, and survival biases across the published medical literature.

Abiotrophia defectiva is recognized by clinicians as a fastidious and virulent bacterium that only rarely establishes infection within the inner lining of the heart and its valve structures. To address this persistent knowledge gap, the study authors designed a comprehensive synthesis of global case reports to delineate baseline patient risk factors, anatomical patterns of involvement, and clinical outcomes.

To assemble the patient dataset, the investigative team executed a systematic literature search across five major electronic databases: PubMed, Web of Science, the China National Knowledge Infrastructure (CNKI), the VIP Database, and the Wanfang databases, capturing all eligible clinical literature published up to October 28, 2025. The inclusion criteria required documented definitive cases of infective endocarditis that met established diagnostic criteria at the time of their original publication, supported by definitive microbiological confirmation of Abiotrophia defectiva. To account for evolving diagnostic standards over time and assess potential classification bias, the researchers systematically reapplied the 2023 European Society of Cardiology (ESC) infective endocarditis diagnostic criteria to each extracted case before performing descriptive statistical analyses on the patient-level records.

The systematic search identified a final cohort of fifty-four individual patients documented across fifty-one published articles. Demographic analysis revealed that the median age of affected patients was 36.6 years, with an interquartile range extending from 16.0 to 53.5 years, while male patients accounted for 61.1 percent of the total group. Underlying cardiovascular conditions were identified in 42.6 percent of the cohort, with congenital heart disease specifically noted in 22.2 percent of all patients. Furthermore, a documented history of an oral procedure or an oral infection was present in 27.8 percent of the cases, underscoring pre-existing cardiac lesions and preceding oral interventions as notable factors associated with the clinical presentation of this fastidious infection.

Anatomical and diagnostic evaluations detailed in the review demonstrated that the infection most frequently damaged the mitral valve, with mitral valve involvement recorded in 59.3 percent of the patient cohort. The clinical course was also marked by diagnostic challenges, as misdiagnosis or formal diagnostic delay occurred in 18.5 percent of cases. Advanced diagnostic modalities proved critical in detecting the pathogen and its structural consequences; among the subset of patients who underwent both transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE), transesophageal imaging successfully identified cardiac vegetations that had been missed by transthoracic imaging in 20.0 percent of cases. Additionally, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was utilized to achieve microbiological identification of Abiotrophia defectiva in 16.7 percent of the reported cases.

Management of the infection frequently required invasive procedures alongside intensive antimicrobial therapy. Overall, 70.4 percent of the fifty-four patients underwent surgery, with 66.7 percent receiving cardiac surgery and 5.6 percent undergoing craniocerebral surgery, including one patient whose medical care required both operative interventions. In terms of medical therapy, every patient whose treatment regimen incorporated vancomycin—totaling twenty-one individuals—achieved documented recovery; however, the authors noted that all twenty-one patients received vancomycin as part of combination therapy, surgical intervention, or both. Because no patient received vancomycin monotherapy, the independent therapeutic effect of the antibiotic could not be evaluated. The most frequently utilized medical regimen across the cohort was a beta-lactam antibiotic administered in combination with gentamicin, with documented recovery occurring in twenty-seven of twenty-eight patients (96.4 percent), though the authors emphasized that this descriptive proportion cannot be directly attributed to the regimen itself.

Across all fifty-four published cases analyzed in the systematic review, only a single in-hospital death was recorded, which the authors attributed to poor general clinical condition. While the short-term outcomes documented in the published medical literature appear favorable, the review authors cautioned that this clinical evidence is of very low certainty.

Subject of Research: Clinical characteristics and management of Abiotrophia defectiva infective endocarditis

Article Title: Abiotrophia defectiva infective endocarditis: a systematic review of published case reports

Article References: Xiang, W., Mu, L., Hong, M., Ahiafor, M., Kong, L., Fu, L., Chen, L., Cao, J., Gao, X., & Liu, F. (2026). Abiotrophia defectiva infective endocarditis: a systematic review of published case reports. Frontiers in Cardiovascular Medicine, 13, Article 1942577. https://doi.org/10.3389/fcvm.2026.1942577

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1942577

Keywords: Abiotrophia defectiva, infective endocarditis, cardiac surgery, mitral valve, transesophageal echocardiography, transthoracic echocardiography, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, vancomycin, gentamicin, beta-lactam antibiotics, craniocerebral surgery, congenital heart disease, oral procedures, diagnostic delay, European Society of Cardiology, systematic review

News Source: Ophelia Keating. (November 14, 2026). Rare Abiotrophia Endocarditis Shows High Surgery Rates in Systematic Case Review. Scienmag.

Tags: Abiotrophia defectivabeta-lactam antibioticsCardiac Surgerycongenital heart diseasecraniocerebral surgerydiagnostic delayEuropean Society of Cardiologygentamicininfective endocarditismatrix-assisted laser desorption/ionization time-of-flight mass spectrometrymitral valveoral proceduressystematic reviewtransesophageal echocardiographytransthoracic echocardiographyvancomycin
Share12Tweet7Share2ShareShareShare1

Related Posts

Dexmedetomidine Is Linked to Improved Renal Recovery Following Cardiac Surgery

Dexmedetomidine Is Linked to Improved Renal Recovery Following Cardiac Surgery

November 19, 2026
Surgical Excision Cured Rare Intraparotid Castleman Disease While Preserving Facial Nerve

Surgical Excision Cured Rare Intraparotid Castleman Disease While Preserving Facial Nerve

November 19, 2026

No Metabolic Crises Occurred With Peripartum Dextrose in Small Observational Study

November 19, 2026

Mental Health Emergency Visits in Saudi Arabia Surge During Late Autumn and Winter

November 19, 2026

POPULAR NEWS

  • No Metabolic Crises Occurred With Peripartum Dextrose in Small Observational Study

    No Metabolic Crises Occurred With Peripartum Dextrose in Small Observational Study

    29 shares
    Share 12 Tweet 7
  • Mental Health Emergency Visits in Saudi Arabia Surge During Late Autumn and Winter

    29 shares
    Share 12 Tweet 7
  • Rare APBA1 Genetic Variants Identified in Children with Severe Monogenic Obesity

    29 shares
    Share 12 Tweet 7
  • RNA Thermometer Controls Recombinant Protein Expression in Engineered Escherichia Coli Cultures

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Dexmedetomidine Is Linked to Improved Renal Recovery Following Cardiac Surgery

Surgical Excision Cured Rare Intraparotid Castleman Disease While Preserving Facial Nerve

No Metabolic Crises Occurred With Peripartum Dextrose in Small Observational Study

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.